Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners.
The healthcare industry has undergone a transformation over the last few decades, with an uptick in outsourcing shining through as a key trend. The benefits of outsourcing research, development or manufacturing activities are multifold – it can cut R&D costs, increase efficiency across the value chain, and allows companies to benefit from expertise they may lack in-house.
However, engaging an outsourcing partner such as a CRO or CDMO comes with its risks. According to Stephanie Gaulding, Managing Director at Pharmatech Associates, the more hands-off approach a sponsor takes, the higher the risk becomes.
Gaulding led a session on strategies for managing outsourcing partners at CPHI North America this week and emphasised the importance of creating a robust oversight framework.
‘You need to have processes in place to control quality and oversee your outsource activities,’ she told conference attendees.
‘Without these processes you can run the risk of things going awry - not having adequate oversight, not making sure that products are made in accordance with the associated regulations.’
Gaulding recommended defining activities that can be delegated early in the process, and clearly outlining these in contractual documents.
She added that the level of oversight a sponsor retains is a crucial consideration – too little can lead to delays and miscommunication, while micromanagement can result in inefficiencies.
She said: ‘What we ultimately want to do is stay in that middle range, where we have tailored oversight that is tweaked and adjusted per the conditions that you’re dealing with. That’s going to get you to optimal efficiency, that’s going to get to robust communication.’
Gaulding encouraged sponsors to create detailed oversight plans, which includes everything about the scope and nature of the engagement with the outsourcing partner. She noted that gaining familiarity with an outsourcing partner’s internal processes and systems can pay dividends, so that requirements imposed on them are manageable and more likely to result in success.
‘I’d encourage everybody to understand your partner’s processes really well, go into it with an open mind and only make adjustments where you absolutely think there needs to be an adjustment,’ she said. ‘Because you’re going to cause them to trip over themselves trying to remember all these additional requirements.’
Gaulding also advised assessing a partner’s risk points, mitigating these where possible, and enacting a change management plan.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance